Researcher Profile

Researcher Profile

Kevin L. Rakszawski, MD

Kevin L. Rakszawski, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
Melanoma and Skin Cancer
klr307@psu.edu

Research Interests

Dr. Kevin Rakszawski's research interests include end-of-life care in patients with hematologic malignancies; lymphoma therapeutics; and prevention and treatment of complications of blood and marrow transplantation.

  • Therapeutics
  • Systematic Reviews
  • Acute Myeloid Leukemia
  • Stem Cells
  • Transplants
  • Survival
  • Whole-Body Irradiation
  • Cyclophosphamide
  • Clofarabine
  • T-Lymphocytes
  • Hodgkin Disease
  • Anaplastic Large-Cell Lymphoma

Clinical Trials

Effect of Omega-3 Fatty Acid, Eicosapentaenoic Acid, and its Metabolites in Combination with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase
bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
WT-1 monitoring for leukemia patients with allogenic transplant
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Phase III study of daratumumab/rHuPH20 (NSC- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC Study)

Recent Publications

2019

Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107

2018

Rakszawski, KL, Miki, K, Claxton, D, Wagner, H, Shike, H, Mineishi, S & Naik, S 2018, 'Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML', International journal of hematology, vol. 108, no. 3, pp. 348-350. https://doi.org/10.1007/s12185-018-2431-5

2017

Leberfinger, AN, Behar, BJ, Williams, NC, Rakszawski, KL, Potochny, JD, MacKay, DR & Ravnic, DJ 2017, 'Breast implant-associated anaplastic large cell lymphoma: A systematic review', JAMA Surgery, vol. 152, no. 12, pp. 1161-1168. https://doi.org/10.1001/jamasurg.2017.4026

2016

Brown, TJ, Brennan, MC, Li, M, Church, EW, Brandmeir, NJ, Rakszawski, KL, Patel, AS, Rizk, EB, Suki, D, Sawaya, R & Glantz, M 2016, 'Association of the extent of resection with survival in glioblastoma a systematic review and meta-Analysis', JAMA Oncology, vol. 2, no. 11, pp. 1460-1469. https://doi.org/10.1001/jamaoncol.2016.1373
Abrams, MJ, Rakszawski, K, Vasekar, M, Passero, F, Abbas, A, Jia, Y & Saif, MW 2016, 'Recent advances in pancreatic cancer: Updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology', Therapeutic Advances in Gastroenterology, vol. 9, no. 2, pp. 141-151. https://doi.org/10.1177/1756283X15622601
Rael, E, Rakszawski, K, Koller, K, Bayerl, M, Butte, M & Zheng, H 2016, 'Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma', Biomarker Research, vol. 4, no. 1, 7. https://doi.org/10.1186/s40364-016-0061-8

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)